On March 31, 2025, the Philippines Food and Drug Administration (FDA) released a draft of Guidelines on the Recall of Authorized Health Products Regulated by the Food and Drug Administration. Built on the earlier draft from December 2023, this new version introduces two key updates: enhanced clarity and transparency in recall procedures, as well as refined report and communication requirements for the marketing authorization holder (MAH).
